South Korea
· Delayed Price · Currency is KRW GeneBioTech Co. ,Ltd Statistics
Total Valuation
GeneBioTech Co. ,Ltd has a market cap or net worth of KRW 29.84 billion. The enterprise value is 22.37 billion.
| Market Cap | 29.84B |
| Enterprise Value | 22.37B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneBioTech Co. ,Ltd has 8.61 million shares outstanding. The number of shares has decreased by -0.18% in one year.
| Shares Outstanding | 8.61M |
| Shares Change (YoY) | -0.18% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.78% |
| Owned by Institutions (%) | n/a |
| Float | 6.09M |
Valuation Ratios
The trailing PE ratio is 12.29.
| PE Ratio | 12.29 |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| PB Ratio | 0.60 |
| P/FCF Ratio | 16.82 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.70, with an EV/FCF ratio of 12.61.
| EV / Earnings | 9.22 |
| EV / Sales | 0.28 |
| EV / EBITDA | 4.70 |
| EV / EBIT | 6.58 |
| EV / FCF | 12.61 |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.93 |
| Quick Ratio | 1.95 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 3.34 |
| Debt / FCF | 8.97 |
| Interest Coverage | 5.46 |
Financial Efficiency
Return on equity (ROE) is 5.03% and return on invested capital (ROIC) is 3.36%.
| Return on Equity (ROE) | 5.03% |
| Return on Assets (ROA) | 3.11% |
| Return on Capital (ROIC) | 3.36% |
| Revenue Per Employee | 2.22B |
| Profits Per Employee | 67.39M |
| Employee Count | 36 |
| Asset Turnover | 1.17 |
| Inventory Turnover | 4.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.50% |
| 50-Day Moving Average | 3,657.40 |
| 200-Day Moving Average | 3,983.65 |
| Relative Strength Index (RSI) | 42.51 |
| Average Volume (20 Days) | 32,423 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GeneBioTech Co. ,Ltd had revenue of KRW 80.03 billion and earned 2.43 billion in profits. Earnings per share was 282.00.
| Revenue | 80.03B |
| Gross Profit | 13.15B |
| Operating Income | 3.40B |
| Pretax Income | 2.89B |
| Net Income | 2.43B |
| EBITDA | 4.76B |
| EBIT | 3.40B |
| Earnings Per Share (EPS) | 282.00 |
Balance Sheet
The company has 23.37 billion in cash and 15.91 billion in debt, giving a net cash position of 7.46 billion or 866.55 per share.
| Cash & Cash Equivalents | 23.37B |
| Total Debt | 15.91B |
| Net Cash | 7.46B |
| Net Cash Per Share | 866.55 |
| Equity (Book Value) | 49.42B |
| Book Value Per Share | 5,738.97 |
| Working Capital | 35.95B |
Cash Flow
In the last 12 months, operating cash flow was 2.07 billion and capital expenditures -294.63 million, giving a free cash flow of 1.77 billion.
| Operating Cash Flow | 2.07B |
| Capital Expenditures | -294.63M |
| Free Cash Flow | 1.77B |
| FCF Per Share | 206.02 |
Margins
Gross margin is 16.44%, with operating and profit margins of 4.25% and 3.03%.
| Gross Margin | 16.44% |
| Operating Margin | 4.25% |
| Pretax Margin | 3.61% |
| Profit Margin | 3.03% |
| EBITDA Margin | 5.94% |
| EBIT Margin | 4.25% |
| FCF Margin | 2.22% |
Dividends & Yields
GeneBioTech Co. ,Ltd does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.18% |
| Shareholder Yield | 0.18% |
| Earnings Yield | 8.14% |
| FCF Yield | 5.95% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GeneBioTech Co. ,Ltd has an Altman Z-Score of 3.53.
| Altman Z-Score | 3.53 |
| Piotroski F-Score | n/a |